Evidence map›Paper›PMID 36334637›Full record

ArticleAntiviral research2022

Putative targeting by BX795 causes decrease in protein kinase C protein levels and inhibition of HSV1 infection.

Rahul K Suryawanshi, Chandrashekhar D Patil, David Wu, Pritam Kumar Panda, Sudhanshu Kumar Singh, Ipsita Volety, Rajeev Ahuja, Yogendra Kumar Mishra, Deepak Shukla

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Emerging drugs for the treatment of herpetic keratitis.Expert opinion on emerging drugs · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Rahul K SuryawanshiDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
Chandrashekhar D PatilDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
David WuDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
Pritam Kumar PandaCondensed Matter Theory Group, Materials Theory Division, Department of Physics and Astronomy, Uppsala University, Box 516, SE, 751 20, Uppsala, Sweden.
Sudhanshu Kumar SinghDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
Ipsita VoletyDepartment of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Rajeev AhujaCondensed Matter Theory Group, Materials Theory Division, Department of Physics and Astronomy, Uppsala University, Box 516, SE, 751 20, Uppsala, Sweden; Department of Physics, Indian Institute of Technology Ropar, Rupnagar, Punjab, 140001, India.
Yogendra Kumar MishraMads Clausen Institute, NanoSYD, University of Southern Denmark, Alsion 2, DK, 6400, Denmark.
Deepak ShuklaDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA; Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL, 60612, USA. Electronic address: dshukla@uic.edu.
University of Illinois Chicago · USUppsala University · SEUniversity of Southern Denmark · DK

Funding

Translational Core for Therapeutic and Diagnostic DevelopmentP30EY001792 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHUKLA, DEEPAK · 1985 to 2025
$14.8M
A new molecular therapy against ocular herpesR01EY024710 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DEEPAK SHUKLA · 2015 to 2026
$5.2M
HPSE in Ocular Herpes InfectionR01EY029426 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DEEPAK SHUKLA · 2018 to 2026
$3.7M
A small molecule inhibitor of HSV genital infectionsR01AI139768 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHUKLA, DEEPAK · 2018 to 2021
$1.6M
NEI NIH HHS P30 EY001792NEI NIH HHS R01 EY024710NEI NIH HHS R01 EY029426NIAID NIH HHS R01 AI139768
6 · The paper itself

Abstract

Herpes simplex virus type-1 (HSV1) exploits cellular machinery for its own replicative advantage. Current treatment modalities against HSV1 cause toxicity and drug resistance issues. In the search for alternative forms of treatment, we have uncovered a small molecule, BX795, as a candidate drug with strong antiviral potential owing to its multitargeted mode of action. In this study, we show that in addition to a previously known mechanism of action, BX795 can directly interact with the proviral host factor protein kinase C (PKC) in silico. When administered to HSV1 or mock infected human corneal epithelial (HCE) cells, BX795 significantly reduces the protein level and perinuclear localization of proviral PKC-α and PKC-ζ isoforms. This activity closely mimics that of a known PKC inhibitor, Bisindolylmaleimide I (BIM I), which also inhibits viral replication. Taken together our studies demonstrate a previously unknown mechanism by which BX795 exerts its antiviral potential.

Indexed as

Herpes SimplexHerpesviridae InfectionsHerpesvirus 1, HumanAntiviral AgentsHumansProtein Kinase CPyrimidinesThiophenesAntiviral AgentsBX795Protein Kinase CPyrimidinesThiophenesAntiviralBX795HerpesvirusMechanismProtein kinase C

Identifiers

PMID36334637
PMCPMC12558078
OpenAlexW4308294176

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.